Psychedelics – News and Features

Article
What Does 2024 Have in Store for Psychedelic Science?
The hype and promise around psychedelic drug trials have accelerated legislation to liberalize access to these compounds. In this article, we delve into the pivotal events in psychedelic science that researchers in the field predict will shape the year 2024.

News
Study Uncovers How Ketamine Works Both Rapidly and Long-Term
New treatments for depression are needed that act rapidly and also have sustained effects. Ketamine could be the answer.

Article
The Next Chapter of Science
Join us as we explore how innovation, ethics and even aesthetics look set to influence the landscape of life science research, creating new possibilities for treating human diseases, feeding our growing population and nurturing the scientists of the future.

News
What Happens in the Human Brain After Taking DMT?
How, exactly, DMT alters brain function to produce positive effects observed in clinical trials is not yet clear, though a study from scientists at Imperial College London has shed some light.

News
African Psychedelic Ibogaine Reduces Veterans’ Brain Injury Symptoms in Small Trial
A traditional African psychedelic drug reduced symptoms of veterans’ brain injury in a small clinical study published in Nature Medicine.

News
Neuropsychological Effects of Rapid-Acting Antidepressants May Explain Their Benefits
New research has identified the neuropsychological effects of rapid-acting antidepressants, like ketamine and psilocybin, that underpin their effectiveness.

News
Unraveling the Psychoactive Psilocybin’s Evolution in “Magic Mushrooms”
A team of researchers have completed the largest genomic diversity study for the genus Psilocybe. Their genomic analysis of 52 Psilocybe specimens includes 39 species that have never been sequenced.

News
Human Beliefs About Drugs Could Have Dose-Dependent Effects on the Brain
Mount Sinai researchers have shown for the first time that a person’s beliefs related to drugs can influence their own brain activity and behavioral responses in a way comparable to the dose-dependent effects of pharmacology.

News
Psychoactive Drug Treats Functional and Neuropsychiatric Symptoms of Brain Injury
Stanford Medicine researchers find that ibogaine, a plant-based psychoactive compound, safely led to improvements in depression, anxiety and functioning among veterans with traumatic brain injuries.

News
Psilocybin-Assisted Therapy Had Success in Treating Depression in Adults With Cancer
Clinical trial results support further study of this psychedelic substance, administered with psychological support from trained therapists, in affected patients.
Advertisement